HU230550B1 - Az amiloidogenikus betegségek megelőzése és kezelése - Google Patents

Info

Publication number

HU230550B1

HU230550B1 HU0201250A HUP0201250A HU230550B1 HU 230550 B1 HU230550 B1 HU 230550B1 HU 0201250 A HU0201250 A HU 0201250A HU P0201250 A HUP0201250 A HU P0201250A HU 230550 B1 HU230550 B1 HU 230550B1

Authority

HU

Hungary

Prior art keywords

peptide

antibody

antibodies

carrier

pbs

Prior art date

1999-05-28

Links

• Espacenet
• Global Dossier
• Discuss

• 238000011282 treatment Methods 0.000 title claims abstract description 101
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 45
• 201000010099 disease Diseases 0.000 title claims abstract description 43
• 108010048112 Amyloidogenic Proteins Proteins 0.000 title description 11
• 102000009091 Amyloidogenic Proteins Human genes 0.000 title description 11
• 230000003942 amyloidogenic effect Effects 0.000 title description 9
• 230000002265 prevention Effects 0.000 title description 7
• 210000004556 brain Anatomy 0.000 claims abstract description 79
• 230000027455 binding Effects 0.000 claims abstract description 51
• 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 47
• 208000037259 Amyloid Plaque Diseases 0.000 claims abstract description 32
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 195
• 239000002671 adjuvant Substances 0.000 claims description 96
• 230000028993 immune response Effects 0.000 claims description 67
• 239000000427 antigen Substances 0.000 claims description 59
• 108091007433 antigens Proteins 0.000 claims description 59
• 102000036639 antigens Human genes 0.000 claims description 59
• 239000012634 fragment Substances 0.000 claims description 58
• 210000001744 T-lymphocyte Anatomy 0.000 claims description 29
• 108020001507 fusion proteins Proteins 0.000 claims description 19
• 102000037865 fusion proteins Human genes 0.000 claims description 19
• 239000008194 pharmaceutical composition Substances 0.000 claims description 17
• 241000700605 Viruses Species 0.000 claims description 14
• 239000002253 acid Substances 0.000 claims description 11
• 102000014914 Carrier Proteins Human genes 0.000 claims description 10
• 108010078791 Carrier Proteins Proteins 0.000 claims description 10
• 229960000814 tetanus toxoid Drugs 0.000 claims description 8
• 230000001580 bacterial effect Effects 0.000 claims description 6
• 230000001413 cellular effect Effects 0.000 claims description 6
• 206010029897 Obsessive thoughts Diseases 0.000 claims description 4
• 239000003937 drug carrier Substances 0.000 claims description 3
• 206010008631 Cholera Diseases 0.000 claims description 2
• 206010043376 Tetanus Diseases 0.000 claims description 2
• 230000002238 attenuated effect Effects 0.000 claims description 2
• 244000052616 bacterial pathogen Species 0.000 claims description 2
• 235000018417 cysteine Nutrition 0.000 claims description 2
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
• 208000002672 hepatitis B Diseases 0.000 claims description 2
• 206010022000 influenza Diseases 0.000 claims description 2
• 230000001919 adrenal effect Effects 0.000 claims 2
• 241001374849 Liparis atlanticus Species 0.000 claims 1
• 108010058846 Ovalbumin Proteins 0.000 claims 1
• 241000282849 Ruminantia Species 0.000 claims 1
• 229930182558 Sterol Natural products 0.000 claims 1
• 229940092253 ovalbumin Drugs 0.000 claims 1
• 150000003432 sterols Chemical class 0.000 claims 1
• 235000003702 sterols Nutrition 0.000 claims 1
• 239000003053 toxin Substances 0.000 claims 1
• 231100000765 toxin Toxicity 0.000 claims 1
• 108700012359 toxins Proteins 0.000 claims 1
• 238000000034 method Methods 0.000 abstract description 135
• 239000003795 chemical substances by application Substances 0.000 abstract description 48
• 230000001225 therapeutic effect Effects 0.000 abstract description 35
• 230000000069 prophylactic effect Effects 0.000 abstract description 11
• 230000009286 beneficial effect Effects 0.000 abstract description 4
• 210000004898 n-terminal fragment Anatomy 0.000 abstract description 4
• 230000009851 immunogenic response Effects 0.000 abstract description 3
• 230000001976 improved effect Effects 0.000 abstract description 2
• 239000002953 phosphate buffered saline Substances 0.000 description 152
• 241000699670 Mus sp. Species 0.000 description 129
• 241001465754 Metazoa Species 0.000 description 126
• 235000001014 amino acid Nutrition 0.000 description 104
• 229940024606 amino acid Drugs 0.000 description 104
• 150000001413 amino acids Chemical class 0.000 description 101
• 230000003053 immunization Effects 0.000 description 89
• 238000002649 immunization Methods 0.000 description 89
• 102000004196 processed proteins & peptides Human genes 0.000 description 75
• 210000004027 cell Anatomy 0.000 description 70
• 230000002163 immunogen Effects 0.000 description 67
• DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 62
• 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 57
• 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 57
• 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 57
• 239000000203 mixture Substances 0.000 description 56
• 230000000694 effects Effects 0.000 description 47
• 210000001519 tissue Anatomy 0.000 description 45
• 238000002347 injection Methods 0.000 description 39
• 239000007924 injection Substances 0.000 description 39
• 230000004044 response Effects 0.000 description 38
• DRHZYJAUECRAJM-DWSYSWFDSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4s,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-8a-[(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-5-[(3s,5s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@@]1(C=O)C)O)C(=O)O[C@@H]1O[C@H](C)[C@@H]([C@@H]([C@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@](O)(CO)CO3)O)[C@H](O)CO2)O)[C@H](C)O1)O)O)OC(=O)C[C@@H](O)C[C@H](OC(=O)C[C@@H](O)C[C@@H]([C@@H](C)CC)O[C@H]1[C@@H]([C@@H](O)[C@H](CO)O1)O)[C@@H](C)CC)C(O)=O)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O DRHZYJAUECRAJM-DWSYSWFDSA-N 0.000 description 37
• 229940035032 monophosphoryl lipid a Drugs 0.000 description 37
• 241000699666 Mus <mouse, genus> Species 0.000 description 35
• 108090000623 proteins and genes Proteins 0.000 description 35
• 239000008280 blood Substances 0.000 description 31
• 210000004369 blood Anatomy 0.000 description 30
• 238000009472 formulation Methods 0.000 description 30
• 210000002966 serum Anatomy 0.000 description 30
• 238000003556 assay Methods 0.000 description 28
• 235000018102 proteins Nutrition 0.000 description 25
• 102000004169 proteins and genes Human genes 0.000 description 25
• 230000007423 decrease Effects 0.000 description 24
• 239000000243 solution Substances 0.000 description 23
• 238000005259 measurement Methods 0.000 description 21
• 108060003951 Immunoglobulin Proteins 0.000 description 20
• 102000018358 immunoglobulin Human genes 0.000 description 20
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
• 230000001965 increasing effect Effects 0.000 description 19
• 229940037003 alum Drugs 0.000 description 18
• 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 18
• 238000002965 ELISA Methods 0.000 description 17
• 230000003941 amyloidogenesis Effects 0.000 description 17
• 239000000872 buffer Substances 0.000 description 17
• 239000003814 drug Substances 0.000 description 17
• 238000012360 testing method Methods 0.000 description 17
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
• 210000003719 b-lymphocyte Anatomy 0.000 description 16
• 238000000151 deposition Methods 0.000 description 16
• 230000008021 deposition Effects 0.000 description 16
• 229920001184 polypeptide Polymers 0.000 description 16
• 230000009261 transgenic effect Effects 0.000 description 16
• 239000013598 vector Substances 0.000 description 16
• 230000001054 cortical effect Effects 0.000 description 15
• 238000002474 experimental method Methods 0.000 description 15
• 238000010191 image analysis Methods 0.000 description 15
• 238000002360 preparation method Methods 0.000 description 15
• 230000009467 reduction Effects 0.000 description 15
• 239000000725 suspension Substances 0.000 description 15
• 241000283973 Oryctolagus cuniculus Species 0.000 description 14
• 230000002829 reductive effect Effects 0.000 description 14
• 238000012216 screening Methods 0.000 description 14
• 230000005875 antibody response Effects 0.000 description 13
• 230000003247 decreasing effect Effects 0.000 description 13
• 241001529936 Murinae Species 0.000 description 12
• 239000000969 carrier Substances 0.000 description 12
• 230000004927 fusion Effects 0.000 description 12
• 239000000463 material Substances 0.000 description 12
• 230000035772 mutation Effects 0.000 description 12
• 230000009257 reactivity Effects 0.000 description 12
• YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 11
• BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 11
• 210000004899 c-terminal region Anatomy 0.000 description 11
• PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 11
• 230000001404 mediated effect Effects 0.000 description 11
• 239000011780 sodium chloride Substances 0.000 description 11
• 229940031439 squalene Drugs 0.000 description 11
• TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 11
• 208000024891 symptom Diseases 0.000 description 11
• ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 10
• 239000003153 chemical reaction reagent Substances 0.000 description 10
• 150000001875 compounds Chemical class 0.000 description 10
• 238000001514 detection method Methods 0.000 description 10
• 230000000971 hippocampal effect Effects 0.000 description 10
• 210000001320 hippocampus Anatomy 0.000 description 10
• 238000006467 substitution reaction Methods 0.000 description 10
• 229940124597 therapeutic agent Drugs 0.000 description 10
• 238000011830 transgenic mouse model Methods 0.000 description 10
• 241000282693 Cercopithecidae Species 0.000 description 9
• 238000010790 dilution Methods 0.000 description 9
• 239000012895 dilution Substances 0.000 description 9
• 238000004519 manufacturing process Methods 0.000 description 9
• 210000000274 microglia Anatomy 0.000 description 9
• 241000699660 Mus musculus Species 0.000 description 8
• 206010057249 Phagocytosis Diseases 0.000 description 8
• 125000003275 alpha amino acid group Chemical group 0.000 description 8
• 210000001638 cerebellum Anatomy 0.000 description 8
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 8
• 238000011161 development Methods 0.000 description 8
• 230000001939 inductive effect Effects 0.000 description 8
• 239000002609 medium Substances 0.000 description 8
• 230000008782 phagocytosis Effects 0.000 description 8
• 238000000746 purification Methods 0.000 description 8
• 239000000523 sample Substances 0.000 description 8
• 102000004127 Cytokines Human genes 0.000 description 7
• 108090000695 Cytokines Proteins 0.000 description 7
• 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 7
• 102100022338 Integrin alpha-M Human genes 0.000 description 7
• 241001494479 Pecora Species 0.000 description 7
• 125000000539 amino acid group Chemical group 0.000 description 7
• 238000004458 analytical method Methods 0.000 description 7
• 229960004198 guanidine Drugs 0.000 description 7
• 108020004707 nucleic acids Proteins 0.000 description 7
• 102000039446 nucleic acids Human genes 0.000 description 7
• 150000007523 nucleic acids Chemical class 0.000 description 7
• 239000000126 substance Substances 0.000 description 7
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 7
• 229940033663 thimerosal Drugs 0.000 description 7
• 241000700198 Cavia Species 0.000 description 6
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
• 201000010374 Down Syndrome Diseases 0.000 description 6
• 206010018341 Gliosis Diseases 0.000 description 6
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
• 241000282412 Homo Species 0.000 description 6
• 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 6
• 101000962498 Macropis fulvipes Macropin Proteins 0.000 description 6
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
• 230000000890 antigenic effect Effects 0.000 description 6
• 210000003169 central nervous system Anatomy 0.000 description 6
• 238000006243 chemical reaction Methods 0.000 description 6
• 238000003745 diagnosis Methods 0.000 description 6
• 239000003085 diluting agent Substances 0.000 description 6
• 210000004408 hybridoma Anatomy 0.000 description 6
• 238000012544 monitoring process Methods 0.000 description 6
• 239000013642 negative control Substances 0.000 description 6
• 239000007764 o/w emulsion Substances 0.000 description 6
• 238000002823 phage display Methods 0.000 description 6
• 210000001539 phagocyte Anatomy 0.000 description 6
• 108091033319 polynucleotide Proteins 0.000 description 6
• 102000040430 polynucleotide Human genes 0.000 description 6
• 239000002157 polynucleotide Substances 0.000 description 6
• 239000013641 positive control Substances 0.000 description 6
• 230000008569 process Effects 0.000 description 6
• 239000007787 solid Substances 0.000 description 6
• 210000004989 spleen cell Anatomy 0.000 description 6
• 238000007920 subcutaneous administration Methods 0.000 description 6
• 241000894006 Bacteria Species 0.000 description 5
• 102000009109 Fc receptors Human genes 0.000 description 5
• 108010087819 Fc receptors Proteins 0.000 description 5
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
• -1 MPL TM Chemical compound 0.000 description 5
• 241000124008 Mammalia Species 0.000 description 5
• CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 5
• 241000283984 Rodentia Species 0.000 description 5
• 239000004480 active ingredient Substances 0.000 description 5
• 210000001130 astrocyte Anatomy 0.000 description 5
• 239000005018 casein Substances 0.000 description 5
• BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 5
• 235000021240 caseins Nutrition 0.000 description 5
• 230000001419 dependent effect Effects 0.000 description 5
• 238000013461 design Methods 0.000 description 5
• SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 5
• 235000019820 disodium diphosphate Nutrition 0.000 description 5
• 239000002158 endotoxin Substances 0.000 description 5
• 230000006870 function Effects 0.000 description 5
• 229940072221 immunoglobulins Drugs 0.000 description 5
• 238000003364 immunohistochemistry Methods 0.000 description 5
• 230000001575 pathological effect Effects 0.000 description 5
• 230000007170 pathology Effects 0.000 description 5
• 239000012071 phase Substances 0.000 description 5
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
• 229920000053 polysorbate 80 Polymers 0.000 description 5
• 239000000843 powder Substances 0.000 description 5
• 238000011160 research Methods 0.000 description 5
• 239000001488 sodium phosphate Substances 0.000 description 5
• 229910000162 sodium phosphate Inorganic materials 0.000 description 5
• 230000009870 specific binding Effects 0.000 description 5
• 210000000952 spleen Anatomy 0.000 description 5
• 239000007858 starting material Substances 0.000 description 5
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 5
• 240000003291 Armoracia rusticana Species 0.000 description 4
• 235000011330 Armoracia rusticana Nutrition 0.000 description 4
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
• 238000009007 Diagnostic Kit Methods 0.000 description 4
• 102000004190 Enzymes Human genes 0.000 description 4
• 108090000790 Enzymes Proteins 0.000 description 4
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
• 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 4
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
• PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
• PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 4
• 230000005867 T cell response Effects 0.000 description 4
• 108700019146 Transgenes Proteins 0.000 description 4
• 230000002159 abnormal effect Effects 0.000 description 4
• 150000007513 acids Chemical class 0.000 description 4
• 229910052782 aluminium Inorganic materials 0.000 description 4
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
• 208000037875 astrocytosis Diseases 0.000 description 4
• 230000007341 astrogliosis Effects 0.000 description 4
• 230000008499 blood brain barrier function Effects 0.000 description 4
• 210000001218 blood-brain barrier Anatomy 0.000 description 4
• 230000036755 cellular response Effects 0.000 description 4
• 230000002490 cerebral effect Effects 0.000 description 4
• 230000008859 change Effects 0.000 description 4
• 229940079593 drug Drugs 0.000 description 4
• 239000000839 emulsion Substances 0.000 description 4
• 239000013604 expression vector Substances 0.000 description 4
• 239000012530 fluid Substances 0.000 description 4
• 210000002443 helper t lymphocyte Anatomy 0.000 description 4
• 238000003018 immunoassay Methods 0.000 description 4
• 238000007912 intraperitoneal administration Methods 0.000 description 4
• 239000007788 liquid Substances 0.000 description 4
• 210000004698 lymphocyte Anatomy 0.000 description 4
• 238000013507 mapping Methods 0.000 description 4
• 230000002025 microglial effect Effects 0.000 description 4
• 210000001616 monocyte Anatomy 0.000 description 4
• 239000000178 monomer Substances 0.000 description 4
• 210000002241 neurite Anatomy 0.000 description 4
• 239000002245 particle Substances 0.000 description 4
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
• 230000002062 proliferating effect Effects 0.000 description 4
• 230000035755 proliferation Effects 0.000 description 4
• 102000005962 receptors Human genes 0.000 description 4
• 108020003175 receptors Proteins 0.000 description 4
• 230000001105 regulatory effect Effects 0.000 description 4
• 239000007790 solid phase Substances 0.000 description 4
• 208000000044 Amnesia Diseases 0.000 description 3
• 241000271566 Aves Species 0.000 description 3
• 239000004593 Epoxy Substances 0.000 description 3
• 241000283073 Equus caballus Species 0.000 description 3
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
• 239000004471 Glycine Substances 0.000 description 3
• 101000823051 Homo sapiens Amyloid-beta precursor protein Proteins 0.000 description 3
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 3
• 201000006347 Intellectual Disability Diseases 0.000 description 3
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
• 102100039564 Leukosialin Human genes 0.000 description 3
• 239000004472 Lysine Substances 0.000 description 3
• 208000026139 Memory disease Diseases 0.000 description 3
• 208000036626 Mental retardation Diseases 0.000 description 3
• 229910019142 PO4 Inorganic materials 0.000 description 3
• 229920001213 Polysorbate 20 Polymers 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 241000700159 Rattus Species 0.000 description 3
• 206010057190 Respiratory tract infections Diseases 0.000 description 3
• 239000006180 TBST buffer Substances 0.000 description 3
• 101150008356 Trio gene Proteins 0.000 description 3
• 239000013504 Triton X-100 Substances 0.000 description 3
• 229920004890 Triton X-100 Polymers 0.000 description 3
• 208000027418 Wounds and injury Diseases 0.000 description 3
• ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 3
• 238000013459 approach Methods 0.000 description 3
• 235000003704 aspartic acid Nutrition 0.000 description 3
• 239000012911 assay medium Substances 0.000 description 3
• 230000015572 biosynthetic process Effects 0.000 description 3
• 230000000903 blocking effect Effects 0.000 description 3
• 230000037396 body weight Effects 0.000 description 3
• 229940098773 bovine serum albumin Drugs 0.000 description 3
• 210000005013 brain tissue Anatomy 0.000 description 3
• 210000002421 cell wall Anatomy 0.000 description 3
• 210000003710 cerebral cortex Anatomy 0.000 description 3
• 210000000349 chromosome Anatomy 0.000 description 3
• 230000006378 damage Effects 0.000 description 3
• 239000008367 deionised water Substances 0.000 description 3
• 229910021641 deionized water Inorganic materials 0.000 description 3
• 150000002148 esters Chemical class 0.000 description 3
• 238000011156 evaluation Methods 0.000 description 3
• 230000002068 genetic effect Effects 0.000 description 3
• 244000144993 groups of animals Species 0.000 description 3
• 230000012010 growth Effects 0.000 description 3
• 102000046783 human APP Human genes 0.000 description 3
• 230000005847 immunogenicity Effects 0.000 description 3
• 238000002991 immunohistochemical analysis Methods 0.000 description 3
• 230000003308 immunostimulating effect Effects 0.000 description 3
• 238000001727 in vivo Methods 0.000 description 3
• 239000000411 inducer Substances 0.000 description 3
• 238000003780 insertion Methods 0.000 description 3
• 230000037431 insertion Effects 0.000 description 3
• 238000007917 intracranial administration Methods 0.000 description 3
• 230000003902 lesion Effects 0.000 description 3
• 239000002502 liposome Substances 0.000 description 3
• 210000004962 mammalian cell Anatomy 0.000 description 3
• 230000006984 memory degeneration Effects 0.000 description 3
• 208000023060 memory loss Diseases 0.000 description 3
• 239000002052 molecular layer Substances 0.000 description 3
• 230000001537 neural effect Effects 0.000 description 3
• 230000002981 neuropathic effect Effects 0.000 description 3
• 239000008188 pellet Substances 0.000 description 3
• 230000002093 peripheral effect Effects 0.000 description 3
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
• 239000010452 phosphate Substances 0.000 description 3
• 210000002381 plasma Anatomy 0.000 description 3
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
• 230000003449 preventive effect Effects 0.000 description 3
• 238000003259 recombinant expression Methods 0.000 description 3
• 150000003839 salts Chemical class 0.000 description 3
• 238000003118 sandwich ELISA Methods 0.000 description 3
• 241000894007 species Species 0.000 description 3
• 238000010186 staining Methods 0.000 description 3
• 239000004575 stone Substances 0.000 description 3
• 239000000829 suppository Substances 0.000 description 3
• 238000013268 sustained release Methods 0.000 description 3
• 239000012730 sustained-release form Substances 0.000 description 3
• 210000002435 tendon Anatomy 0.000 description 3
• 230000000699 topical effect Effects 0.000 description 3
• 238000012546 transfer Methods 0.000 description 3
• 229960005486 vaccine Drugs 0.000 description 3
• 239000013603 viral vector Substances 0.000 description 3
• HONKEGXLWUDTCF-YFKPBYRVSA-N (2s)-2-amino-2-methyl-4-phosphonobutanoic acid Chemical compound OC(=O)[C@](N)(C)CCP(O)(O)=O HONKEGXLWUDTCF-YFKPBYRVSA-N 0.000 description 2
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
• 101800000263 Acidic protein Proteins 0.000 description 2
• 102100034112 Alkyldihydroxyacetonephosphate synthase, peroxisomal Human genes 0.000 description 2
• 241000272478 Aquila Species 0.000 description 2
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
• 241000283707 Capra Species 0.000 description 2
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
• 241000700199 Cavia porcellus Species 0.000 description 2
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
• 108010062580 Concanavalin A Proteins 0.000 description 2
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
• 108010084884 GDP-mannose transporter Proteins 0.000 description 2
• 101000799143 Homo sapiens Alkyldihydroxyacetonephosphate synthase, peroxisomal Proteins 0.000 description 2
• 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 2
• 101000616438 Homo sapiens Microtubule-associated protein 4 Proteins 0.000 description 2
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
• 241000282567 Macaca fascicularis Species 0.000 description 2
• 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
• 102100021794 Microtubule-associated protein 4 Human genes 0.000 description 2
• 108700020354 N-acetylmuramyl-threonyl-isoglutamine Proteins 0.000 description 2
• 206010028980 Neoplasm Diseases 0.000 description 2
• 206010029240 Neuritis Diseases 0.000 description 2
• 108091028043 Nucleic acid sequence Proteins 0.000 description 2
• 229930040373 Paraformaldehyde Natural products 0.000 description 2
• 229930182555 Penicillin Natural products 0.000 description 2
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 241000288906 Primates Species 0.000 description 2
• 206010037660 Pyrexia Diseases 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 2
• 206010044688 Trisomy 21 Diseases 0.000 description 2
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
• 230000004913 activation Effects 0.000 description 2
• 125000003277 amino group Chemical group 0.000 description 2
• BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
• 238000000848 angular dependent Auger electron spectroscopy Methods 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 101150031224 app gene Proteins 0.000 description 2
• 125000003118 aryl group Chemical group 0.000 description 2
• 239000012131 assay buffer Substances 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
• 230000001588 bifunctional effect Effects 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 210000001185 bone marrow Anatomy 0.000 description 2
• 244000309466 calf Species 0.000 description 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
• 238000005119 centrifugation Methods 0.000 description 2
• 238000003776 cleavage reaction Methods 0.000 description 2
• 238000010367 cloning Methods 0.000 description 2
• 238000012875 competitive assay Methods 0.000 description 2
• 230000024203 complement activation Effects 0.000 description 2
• 230000021615 conjugation Effects 0.000 description 2
• 239000000470 constituent Substances 0.000 description 2
• 238000010168 coupling process Methods 0.000 description 2
• 238000005859 coupling reaction Methods 0.000 description 2
• 230000005786 degenerative changes Effects 0.000 description 2
• 239000003599 detergent Substances 0.000 description 2
• 238000002405 diagnostic procedure Methods 0.000 description 2
• 208000035475 disorder Diseases 0.000 description 2
• 238000009826 distribution Methods 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• 210000001353 entorhinal cortex Anatomy 0.000 description 2
• 239000000284 extract Substances 0.000 description 2
• 239000007789 gas Substances 0.000 description 2
• 238000001415 gene therapy Methods 0.000 description 2
• 239000011521 glass Substances 0.000 description 2
• 230000002518 glial effect Effects 0.000 description 2
• 230000007387 gliosis Effects 0.000 description 2
• 150000004676 glycans Chemical class 0.000 description 2
• 239000001963 growth medium Substances 0.000 description 2
• 210000003128 head Anatomy 0.000 description 2
• 230000002489 hematologic effect Effects 0.000 description 2
• 210000004754 hybrid cell Anatomy 0.000 description 2
• 230000002519 immonomodulatory effect Effects 0.000 description 2
• 230000001900 immune effect Effects 0.000 description 2
• 229960001438 immunostimulant agent Drugs 0.000 description 2
• 239000003022 immunostimulating agent Substances 0.000 description 2
• 239000007943 implant Substances 0.000 description 2
• 238000000338 in vitro Methods 0.000 description 2
• 230000002779 inactivation Effects 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 210000004969 inflammatory cell Anatomy 0.000 description 2
• 230000028709 inflammatory response Effects 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 208000014674 injury Diseases 0.000 description 2
• 230000003834 intracellular effect Effects 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 150000002500 ions Chemical class 0.000 description 2
• 230000001788 irregular Effects 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 238000002372 labelling Methods 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 208000032839 leukemia Diseases 0.000 description 2
• 239000003446 ligand Substances 0.000 description 2
• 125000005647 linker group Chemical group 0.000 description 2
• 150000002632 lipids Chemical class 0.000 description 2
• 239000008176 lyophilized powder Substances 0.000 description 2
• 210000002540 macrophage Anatomy 0.000 description 2
• 239000011777 magnesium Substances 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 239000003550 marker Substances 0.000 description 2
• 239000011159 matrix material Substances 0.000 description 2
• 244000000010 microbial pathogen Species 0.000 description 2
• 238000000520 microinjection Methods 0.000 description 2
• 239000011859 microparticle Substances 0.000 description 2
• 235000013336 milk Nutrition 0.000 description 2
• 239000008267 milk Substances 0.000 description 2
• 210000004080 milk Anatomy 0.000 description 2
• 230000003278 mimic effect Effects 0.000 description 2
• 239000003226 mitogen Substances 0.000 description 2
• 238000010172 mouse model Methods 0.000 description 2
• 201000000050 myeloid neoplasm Diseases 0.000 description 2
• 210000000822 natural killer cell Anatomy 0.000 description 2
• 210000000944 nerve tissue Anatomy 0.000 description 2
• 230000007935 neutral effect Effects 0.000 description 2
• 210000000440 neutrophil Anatomy 0.000 description 2
• 239000002773 nucleotide Substances 0.000 description 2
• 125000003729 nucleotide group Chemical group 0.000 description 2
• 210000004940 nucleus Anatomy 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 235000019198 oils Nutrition 0.000 description 2
• 238000004806 packaging method and process Methods 0.000 description 2
• 229920002866 paraformaldehyde Polymers 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• 229940049954 penicillin Drugs 0.000 description 2
• 238000010647 peptide synthesis reaction Methods 0.000 description 2
• 239000008363 phosphate buffer Substances 0.000 description 2
• 239000006187 pill Substances 0.000 description 2
• 239000000902 placebo Substances 0.000 description 2
• 229940068196 placebo Drugs 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 229920000642 polymer Polymers 0.000 description 2
• 229920001282 polysaccharide Polymers 0.000 description 2
• 239000005017 polysaccharide Substances 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 238000011321 prophylaxis Methods 0.000 description 2
• 230000001681 protective effect Effects 0.000 description 2
• 230000010076 replication Effects 0.000 description 2
• 230000004043 responsiveness Effects 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 230000007017 scission Effects 0.000 description 2
• 230000003248 secreting effect Effects 0.000 description 2
• 238000013207 serial dilution Methods 0.000 description 2
• MIDXXTLMKGZDPV-UHFFFAOYSA-M sodium;1-[6-(2,5-dioxopyrrol-1-yl)hexanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCN1C(=O)C=CC1=O MIDXXTLMKGZDPV-UHFFFAOYSA-M 0.000 description 2
• 230000000638 stimulation Effects 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• 235000013616 tea Nutrition 0.000 description 2
• 231100000027 toxicology Toxicity 0.000 description 2
• 231100000041 toxicology testing Toxicity 0.000 description 2
• 238000001890 transfection Methods 0.000 description 2
• 230000001131 transforming effect Effects 0.000 description 2
• 238000011820 transgenic animal model Methods 0.000 description 2
• 230000001960 triggered effect Effects 0.000 description 2
• GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
• 102000003390 tumor necrosis factor Human genes 0.000 description 2
• 210000003462 vein Anatomy 0.000 description 2
• 230000003612 virological effect Effects 0.000 description 2
• 239000011534 wash buffer Substances 0.000 description 2
• 238000001262 western blot Methods 0.000 description 2
• 239000002023 wood Substances 0.000 description 2
• HDTRYLNUVZCQOY-UHFFFAOYSA-N &alpha;-D-glucopyranosyl-&alpha;-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
• HTGPNFWIXOPNIF-UHFFFAOYSA-N (2,5-dioxopyrrol-1-yl) hexanoate Chemical compound CCCCCC(=O)ON1C(=O)C=CC1=O HTGPNFWIXOPNIF-UHFFFAOYSA-N 0.000 description 1
• YHQZWWDVLJPRIF-JLHRHDQISA-N (4R)-4-[[(2S,3R)-2-[acetyl-[(3R,4R,5S,6R)-3-amino-4-[(1R)-1-carboxyethoxy]-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoic acid Chemical compound C(C)(=O)N([C@@H]([C@H](O)C)C(=O)N[C@H](CCC(=O)O)C(N)=O)C1[C@H](N)[C@@H](O[C@@H](C(=O)O)C)[C@H](O)[C@H](O1)CO YHQZWWDVLJPRIF-JLHRHDQISA-N 0.000 description 1
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
• 102100030492 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase epsilon-1 Human genes 0.000 description 1
• GHIVDTCFLFLOBV-UHFFFAOYSA-N 2-(diethylamino)ethyl 2-acetyloxybenzoate Chemical compound CCN(CC)CCOC(=O)C1=CC=CC=C1OC(C)=O GHIVDTCFLFLOBV-UHFFFAOYSA-N 0.000 description 1
• BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
• WYVVKGNFXHOCQV-UHFFFAOYSA-N 3-iodoprop-2-yn-1-yl butylcarbamate Chemical compound CCCCNC(=O)OCC#CI WYVVKGNFXHOCQV-UHFFFAOYSA-N 0.000 description 1
• 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
• QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
• 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
• 229940117976 5-hydroxylysine Drugs 0.000 description 1
• 108700028369 Alleles Proteins 0.000 description 1
• 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
• 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
• 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
• 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
• 208000031295 Animal disease Diseases 0.000 description 1
• 108010032595 Antibody Binding Sites Proteins 0.000 description 1
• 101100028789 Arabidopsis thaliana PBS1 gene Proteins 0.000 description 1
• 241001081972 Arctium medians Species 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 206010003445 Ascites Diseases 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 201000001320 Atherosclerosis Diseases 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• 238000000035 BCA protein assay Methods 0.000 description 1
• 231100000699 Bacterial toxin Toxicity 0.000 description 1
• 102100027883 Bardet-Biedl syndrome 2 protein Human genes 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 101800001415 Bri23 peptide Proteins 0.000 description 1
• 241000195940 Bryophyta Species 0.000 description 1
• 101800000655 C-terminal peptide Proteins 0.000 description 1
• 102400000107 C-terminal peptide Human genes 0.000 description 1
• 108091007914 CDKs Proteins 0.000 description 1
• 102220596352 CUGBP Elav-like family member 1_L12I_mutation Human genes 0.000 description 1
• 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 1
• 101100245381 Caenorhabditis elegans pbs-6 gene Proteins 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 206010051290 Central nervous system lesion Diseases 0.000 description 1
• 241001227713 Chiron Species 0.000 description 1
• 102000009016 Cholera Toxin Human genes 0.000 description 1
• 108010049048 Cholera Toxin Proteins 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 241001091551 Clio Species 0.000 description 1
• 108010078015 Complement C3b Proteins 0.000 description 1
• 108091035707 Consensus sequence Proteins 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• 241000759568 Corixa Species 0.000 description 1
• 241000557626 Corvus corax Species 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• 241000252233 Cyprinus carpio Species 0.000 description 1
• 150000008574 D-amino acids Chemical class 0.000 description 1
• YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• 206010012289 Dementia Diseases 0.000 description 1
• 208000031124 Dementia Alzheimer type Diseases 0.000 description 1
• 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
• 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 201000004624 Dermatitis Diseases 0.000 description 1
• 201000004449 Diamond-Blackfan anemia Diseases 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
• 241000709744 Enterobacterio phage MS2 Species 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• 241000218218 Ficus <angiosperm> Species 0.000 description 1
• 238000006424 Flood reaction Methods 0.000 description 1
• 241001137350 Fratercula Species 0.000 description 1
• 241000237858 Gastropoda Species 0.000 description 1
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
• 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
• 244000068988 Glycine max Species 0.000 description 1
• 235000010469 Glycine max Nutrition 0.000 description 1
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
• 239000012981 Hank's balanced salt solution Substances 0.000 description 1
• 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 101100268553 Homo sapiens APP gene Proteins 0.000 description 1
• 101100408465 Homo sapiens PLCE1 gene Proteins 0.000 description 1
• 101100244921 Homo sapiens PRDX1 gene Proteins 0.000 description 1
• 101000595669 Homo sapiens Pituitary homeobox 2 Proteins 0.000 description 1
• 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
• 101000699781 Homo sapiens Retrotransposon Gag-like protein 4 Proteins 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• 108091006905 Human Serum Albumin Proteins 0.000 description 1
• 102000008100 Human Serum Albumin Human genes 0.000 description 1
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
• 206010061598 Immunodeficiency Diseases 0.000 description 1
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
• 108700029228 Immunoglobulin Heavy Chain Genes Proteins 0.000 description 1
• 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
• 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
• 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
• 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 241000283160 Inia Species 0.000 description 1
• 108010002350 Interleukin-2 Proteins 0.000 description 1
• 241000764238 Isis Species 0.000 description 1
• 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
• 229930182816 L-glutamine Natural products 0.000 description 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
• 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 108010005832 Leukosialin Proteins 0.000 description 1
• GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• 102000043131 MHC class II family Human genes 0.000 description 1
• 108091054438 MHC class II family Proteins 0.000 description 1
• 108010048188 MS2 polymerase Proteins 0.000 description 1
• 235000014435 Mentha Nutrition 0.000 description 1
• 241001072983 Mentha Species 0.000 description 1
• 108010020004 Microtubule-Associated Proteins Proteins 0.000 description 1
• 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 1
• 241001092142 Molina Species 0.000 description 1
• JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
• AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 1
• PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 description 1
• 108010049175 N-substituted Glycines Proteins 0.000 description 1
• 101800000597 N-terminal peptide Proteins 0.000 description 1
• 102400000108 N-terminal peptide Human genes 0.000 description 1
• 238000005481 NMR spectroscopy Methods 0.000 description 1
• 238000011887 Necropsy Methods 0.000 description 1
• 241001391926 Neea Species 0.000 description 1
• SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
• 239000004677 Nylon Substances 0.000 description 1
• 240000001155 Opuntia dillenii Species 0.000 description 1
• 235000006544 Opuntia dillenii Nutrition 0.000 description 1
• 240000007594 Oryza sativa Species 0.000 description 1
• 235000007164 Oryza sativa Nutrition 0.000 description 1
• 208000012868 Overgrowth Diseases 0.000 description 1
• 101150084935 PTER gene Proteins 0.000 description 1
• 240000001090 Papaver somniferum Species 0.000 description 1
• 235000008753 Papaver somniferum Nutrition 0.000 description 1
• 241001631646 Papillomaviridae Species 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 108010067902 Peptide Library Proteins 0.000 description 1
• 102000003992 Peroxidases Human genes 0.000 description 1
• 102100029139 Peroxiredoxin-1 Human genes 0.000 description 1
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
• 102100036090 Pituitary homeobox 2 Human genes 0.000 description 1
• 108010020346 Polyglutamic Acid Proteins 0.000 description 1
• 101710182846 Polyhedrin Proteins 0.000 description 1
• 108010050254 Presenilins Proteins 0.000 description 1
• 108010067787 Proteoglycans Proteins 0.000 description 1
• 102000016611 Proteoglycans Human genes 0.000 description 1
• 241001092473 Quillaja Species 0.000 description 1
• 235000009001 Quillaja saponaria Nutrition 0.000 description 1
• 101150085390 RPM1 gene Proteins 0.000 description 1
• 239000012980 RPMI-1640 medium Substances 0.000 description 1
• 101150045592 RSC1 gene Proteins 0.000 description 1
• 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
• 102100029131 Retrotransposon Gag-like protein 4 Human genes 0.000 description 1
• 108091058545 Secretory proteins Proteins 0.000 description 1
• 102000040739 Secretory proteins Human genes 0.000 description 1
• 229920002684 Sepharose Polymers 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 241001062472 Stokellia anisodon Species 0.000 description 1
• 108010090804 Streptavidin Proteins 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
• 102000019355 Synuclein Human genes 0.000 description 1
• 108050006783 Synuclein Proteins 0.000 description 1
• 230000024932 T cell mediated immunity Effects 0.000 description 1
• 101150084279 TM gene Proteins 0.000 description 1
• 241001080024 Telles Species 0.000 description 1
• 244000269722 Thea sinensis Species 0.000 description 1
• 241001197925 Theila Species 0.000 description 1
• 244000299461 Theobroma cacao Species 0.000 description 1
• 235000009470 Theobroma cacao Nutrition 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 208000002474 Tinea Diseases 0.000 description 1
• HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
• 241000893966 Trichophyton verrucosum Species 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 208000037386 Typhoid Diseases 0.000 description 1
• 101150117115 V gene Proteins 0.000 description 1
• 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 1
• 244000291414 Vaccinium oxycoccus Species 0.000 description 1
• 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 1
• 241000711975 Vesicular stomatitis virus Species 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 210000001642 activated microglia Anatomy 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 210000004100 adrenal gland Anatomy 0.000 description 1
• 238000012382 advanced drug delivery Methods 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 238000001261 affinity purification Methods 0.000 description 1
• 238000013019 agitation Methods 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• 229940024545 aluminum hydroxide Drugs 0.000 description 1
• 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
• 229940009859 aluminum phosphate Drugs 0.000 description 1
• SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 210000004381 amniotic fluid Anatomy 0.000 description 1
• 239000012491 analyte Substances 0.000 description 1
• 239000003098 androgen Substances 0.000 description 1
• 230000002882 anti-plaque Effects 0.000 description 1
• 238000009175 antibody therapy Methods 0.000 description 1
• 230000030741 antigen processing and presentation Effects 0.000 description 1
• 239000012062 aqueous buffer Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 125000003435 aroyl group Chemical group 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• 108010030694 avidin-horseradish peroxidase complex Proteins 0.000 description 1
• 230000003376 axonal effect Effects 0.000 description 1
• 150000001540 azides Chemical class 0.000 description 1
• 239000000688 bacterial toxin Substances 0.000 description 1
• 239000003855 balanced salt solution Substances 0.000 description 1
• 239000003637 basic solution Substances 0.000 description 1
• 210000003651 basophil Anatomy 0.000 description 1
• 208000013404 behavioral symptom Diseases 0.000 description 1
• 230000003542 behavioural effect Effects 0.000 description 1
• WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical group OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• 125000004057 biotinyl group Chemical group [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
• 230000002051 biphasic effect Effects 0.000 description 1
• 210000000601 blood cell Anatomy 0.000 description 1
• 238000004820 blood count Methods 0.000 description 1
• 230000036765 blood level Effects 0.000 description 1
• 229910021538 borax Inorganic materials 0.000 description 1
• 230000006931 brain damage Effects 0.000 description 1
• 231100000874 brain damage Toxicity 0.000 description 1
• 208000029028 brain injury Diseases 0.000 description 1
• 210000000133 brain stem Anatomy 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• KDPAWGWELVVRCH-UHFFFAOYSA-N bromoacetic acid Chemical compound OC(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-N 0.000 description 1
• 239000007975 buffered saline Substances 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• OBAORLCNVUQNOP-UHFFFAOYSA-N carboxy 2-hydroxyacetate Chemical compound OCC(=O)OC(O)=O OBAORLCNVUQNOP-UHFFFAOYSA-N 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 230000001364 causal effect Effects 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 238000001516 cell proliferation assay Methods 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 230000002759 chromosomal effect Effects 0.000 description 1
• 238000004140 cleaning Methods 0.000 description 1
• 238000011260 co-administration Methods 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 238000004440 column chromatography Methods 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 230000006957 competitive inhibition Effects 0.000 description 1
• 238000012790 confirmation Methods 0.000 description 1
• 238000004624 confocal microscopy Methods 0.000 description 1
• IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 1
• 210000000795 conjunctiva Anatomy 0.000 description 1
• 239000000356 contaminant Substances 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 239000010949 copper Substances 0.000 description 1
• 210000000877 corpus callosum Anatomy 0.000 description 1
• 210000005257 cortical tissue Anatomy 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 239000007822 coupling agent Substances 0.000 description 1
• 235000004634 cranberry Nutrition 0.000 description 1
• 235000019788 craving Nutrition 0.000 description 1
• 239000003431 cross linking reagent Substances 0.000 description 1
• 230000009260 cross reactivity Effects 0.000 description 1
• 239000008150 cryoprotective solution Substances 0.000 description 1
• 210000005220 cytoplasmic tail Anatomy 0.000 description 1
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
• 238000005034 decoration Methods 0.000 description 1
• 230000003412 degenerative effect Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
• 210000001947 dentate gyrus Anatomy 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 229960000633 dextran sulfate Drugs 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000000378 dietary effect Effects 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 238000000811 diffusing wave spectroscopy Methods 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
• 230000008034 disappearance Effects 0.000 description 1
• 230000006806 disease prevention Effects 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 239000012153 distilled water Substances 0.000 description 1
• 235000013601 eggs Nutrition 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 210000001671 embryonic stem cell Anatomy 0.000 description 1
• 238000004945 emulsification Methods 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 238000006911 enzymatic reaction Methods 0.000 description 1
• 208000028104 epidemic louse-borne typhus Diseases 0.000 description 1
• 210000000981 epithelium Anatomy 0.000 description 1
• 230000003628 erosive effect Effects 0.000 description 1
• YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 238000013401 experimental design Methods 0.000 description 1
• 239000013613 expression plasmid Substances 0.000 description 1
• 210000002744 extracellular matrix Anatomy 0.000 description 1
• 238000013213 extrapolation Methods 0.000 description 1
• 210000003414 extremity Anatomy 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 239000012894 fetal calf serum Substances 0.000 description 1
• 230000003619 fibrillary effect Effects 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 210000002683 foot Anatomy 0.000 description 1
• ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
• 108091007739 gamma-secretases Proteins 0.000 description 1
• 102000038383 gamma-secretases Human genes 0.000 description 1
• 238000001476 gene delivery Methods 0.000 description 1
• 238000003197 gene knockdown Methods 0.000 description 1
• 238000010353 genetic engineering Methods 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 150000002333 glycines Chemical class 0.000 description 1
• 230000002414 glycolytic effect Effects 0.000 description 1
• 230000002710 gonadal effect Effects 0.000 description 1
• PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
• 239000001307 helium Substances 0.000 description 1
• 229910052734 helium Inorganic materials 0.000 description 1
• SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
• 150000002391 heterocyclic compounds Chemical class 0.000 description 1
• 239000000833 heterodimer Substances 0.000 description 1
• 229960002885 histidine Drugs 0.000 description 1
• 230000001744 histochemical effect Effects 0.000 description 1
• 230000001632 homeopathic effect Effects 0.000 description 1
• 230000006801 homologous recombination Effects 0.000 description 1
• 238000002744 homologous recombination Methods 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• 210000002758 humerus Anatomy 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 238000005462 in vivo assay Methods 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 238000011221 initial treatment Methods 0.000 description 1
• 230000015788 innate immune response Effects 0.000 description 1
• 238000011081 inoculation Methods 0.000 description 1
• 102000006495 integrins Human genes 0.000 description 1
• 108010044426 integrins Proteins 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
• 201000008633 iridogoniodysgenesis syndrome Diseases 0.000 description 1
• 229910052742 iron Inorganic materials 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 210000000867 larynx Anatomy 0.000 description 1
• 210000002414 leg Anatomy 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
• 108010052968 leupeptin Proteins 0.000 description 1
• 238000001638 lipofection Methods 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 230000001926 lymphatic effect Effects 0.000 description 1
• 210000004324 lymphatic system Anatomy 0.000 description 1
• 238000002794 lymphocyte assay Methods 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
• 239000001095 magnesium carbonate Substances 0.000 description 1
• 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 238000002595 magnetic resonance imaging Methods 0.000 description 1
• 201000004792 malaria Diseases 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 238000007726 management method Methods 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 206010027175 memory impairment Diseases 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 210000001872 metatarsal bone Anatomy 0.000 description 1
• NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 229910052651 microcline Inorganic materials 0.000 description 1
• 238000000386 microscopy Methods 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 235000014569 mints Nutrition 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 230000004660 morphological change Effects 0.000 description 1
• 235000011929 mousse Nutrition 0.000 description 1
• 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 229910052754 neon Inorganic materials 0.000 description 1
• GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
• 210000005036 nerve Anatomy 0.000 description 1
• 230000004770 neurodegeneration Effects 0.000 description 1
• 230000000626 neurodegenerative effect Effects 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 230000008906 neuronal response Effects 0.000 description 1
• 230000007171 neuropathology Effects 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 238000010606 normalization Methods 0.000 description 1
• 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
• 229920001778 nylon Polymers 0.000 description 1
• 210000000287 oocyte Anatomy 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
• 238000012856 packing Methods 0.000 description 1
• 239000003973 paint Substances 0.000 description 1
• 238000010422 painting Methods 0.000 description 1
• 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 230000005298 paramagnetic effect Effects 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 230000007119 pathological manifestation Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 230000006919 peptide aggregation Effects 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 208000008494 pericarditis Diseases 0.000 description 1
• 206010034674 peritonitis Diseases 0.000 description 1
• 239000012466 permeate Substances 0.000 description 1
• 108040007629 peroxidase activity proteins Proteins 0.000 description 1
• 239000003208 petroleum Substances 0.000 description 1
• 229940067631 phospholipid Drugs 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 230000007505 plaque formation Effects 0.000 description 1
• 239000013612 plasmid Substances 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
• 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 229920000647 polyepoxide Polymers 0.000 description 1
• 229920002643 polyglutamic acid Polymers 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 239000011148 porous material Substances 0.000 description 1
• 230000002516 postimmunization Effects 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 239000011736 potassium bicarbonate Substances 0.000 description 1
• 235000015497 potassium bicarbonate Nutrition 0.000 description 1
• 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
• TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 239000002244 precipitate Substances 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 238000011045 prefiltration Methods 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 238000002203 pretreatment Methods 0.000 description 1
• 230000009290 primary effect Effects 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 239000000047 product Substances 0.000 description 1
• 230000009696 proliferative response Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 150000003180 prostaglandins Chemical class 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 210000001938 protoplast Anatomy 0.000 description 1
• 238000013441 quality evaluation Methods 0.000 description 1
• 238000011158 quantitative evaluation Methods 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 239000011541 reaction mixture Substances 0.000 description 1
• 230000007342 reactive astrogliosis Effects 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 239000001044 red dye Substances 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 230000000284 resting effect Effects 0.000 description 1
• 230000001177 retroviral effect Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 235000009566 rice Nutrition 0.000 description 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
• 239000012723 sample buffer Substances 0.000 description 1
• 231100000241 scar Toxicity 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 238000004062 sedimentation Methods 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 239000002453 shampoo Substances 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• 235000010339 sodium tetraborate Nutrition 0.000 description 1
• 210000004872 soft tissue Anatomy 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 125000006850 spacer group Chemical group 0.000 description 1
• 210000005070 sphincter Anatomy 0.000 description 1
• 238000009987 spinning Methods 0.000 description 1
• 210000004988 splenocyte Anatomy 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 238000003756 stirring Methods 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 208000003265 stomatitis Diseases 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• 229960002317 succinimide Drugs 0.000 description 1
• OORLZFUTLGXMEF-UHFFFAOYSA-N sulfentrazone Chemical compound O=C1N(C(F)F)C(C)=NN1C1=CC(NS(C)(=O)=O)=C(Cl)C=C1Cl OORLZFUTLGXMEF-UHFFFAOYSA-N 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 229910052717 sulfur Inorganic materials 0.000 description 1
• 235000011149 sulphuric acid Nutrition 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 229940104230 thymidine Drugs 0.000 description 1
• 208000008732 thymoma Diseases 0.000 description 1
• 238000004448 titration Methods 0.000 description 1
• 231100000167 toxic agent Toxicity 0.000 description 1
• 239000003440 toxic substance Substances 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000037317 transdermal delivery Effects 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 102000035160 transmembrane proteins Human genes 0.000 description 1
• 108091005703 transmembrane proteins Proteins 0.000 description 1
• 238000011277 treatment modality Methods 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
• 201000008297 typhoid fever Diseases 0.000 description 1
• 206010061393 typhus Diseases 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 210000000689 upper leg Anatomy 0.000 description 1
• 238000002255 vaccination Methods 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 210000005166 vasculature Anatomy 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 238000012800 visualization Methods 0.000 description 1
• 238000003260 vortexing Methods 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 238000002424 x-ray crystallography Methods 0.000 description 1